Montanova Capital, LLC bought $1.9M of BNTC
director, owner at Benitec Biopharma Inc.. 144,223 shares at an average of $13.20, traded Dec 23, 2025, filed Dec 29, 2025.
Score components
- +15RoleDirector
- +25Trade size$1.9M at market
- 0Relative to holdingsHoldings up 1.5%
- +4Price context23% below the 52-week high
- 0ClusterNo other insider buying within 14 days
- +5Repeat buying3 buys in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -10.5%, 3m -25.4%, 6m -5.9%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000899140-25-001479, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Dec 23, 2025 | POpen-market purchase Common stock, par value $0.0001 per shareindirect: See footnotes | +42,600 | $12.85 | $547k | 9,620,075 | Dec 29, 2025 |
| Dec 23, 2025 | POpen-market purchase Common stock, par value $0.0001 per shareindirect: See footnotes | +7,400 | $12.85 | $95k | 1,834,053 | Dec 29, 2025 |
| Dec 26, 2025 | POpen-market purchase Common stock, par value $0.0001 per shareindirect: See footnotes | +14,320 | $13.10 | $188k | 9,634,395 | Dec 29, 2025 |
| Dec 26, 2025 | POpen-market purchase Common stock, par value $0.0001 per shareindirect: See footnotes | +2,516 | $13.10 | $33k | 1,836,569 | Dec 29, 2025 |
| Dec 29, 2025 | POpen-market purchase Common stock, par value $0.0001 per shareindirect: See footnotes | +65,800 | $13.44 | $884k | 9,700,195 | Dec 29, 2025 |
| Dec 29, 2025 | POpen-market purchase Common stock, par value $0.0001 per shareindirect: See footnotes | +11,587 | $13.44 | $156k | 1,848,156 | Dec 29, 2025 |
Related signals
Other insiders at Benitec Biopharma Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 42Moderate | BNTCbuy Benitec Biopharma Inc. | Montanova Capital, LLC director, owner | $539k 46,141 shares | +0% | |
| 47Moderate | BNTCbuy Benitec Biopharma Inc. | Montanova Capital, LLC director, owner | $20M 1,481,481 shares | +17% | |
| 31Weak | BNTCbuy Benitec Biopharma Inc. | Montanova Capital, LLC director, owner | $212k 16,497 shares | +0% | |
| 47Moderate | BNTCbuy Benitec Biopharma Inc. | Montanova Capital, LLC director, owner | $12M 900,000 shares | +11% | |
| 33Weak | BNTCbuy Benitec Biopharma Inc. | Montanova Capital, LLC director, owner | $527k 47,520 shares | +1% | |
| 31Weak | BNTCbuy Benitec Biopharma Inc. | Montanova Capital, LLC director, owner | $403k 42,000 shares | +1% | |
| 26Weak | BNTCbuy Benitec Biopharma Inc. | Montanova Capital, LLC director, owner | $417k 41,436 shares | +1% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.